Literature DB >> 4060108

Evaluation of jet nebulisers for use with gentamicin solution.

S P Newman, P G Pellow, M M Clay, S W Clarke.   

Abstract

Recently nebulised antibiotics (gentamicin and carbenicillin) have been used successfully to treat respiratory tract infection in patients with cystic fibrosis. No information exists, however, on the choice of nebuliser or the ideal mode of operation with antibiotic solutions, which are often viscous. The aerosol output, droplet size, and nebulisation time were assessed for four common brands of jet nebuliser (Bird, DeVilbiss, Inspiron, and Upmist) used to nebulise 2 ml (80 mg) and 4 ml (160 mg) of gentamicin solution (Garamycin, Kirby-Warrick) at four compressed gas flow rates (6, 8, 10, and 12 1 . min-1). There were considerable variations between the nebulisers, DeVilbiss and Upmist being most efficient in the release of respirable (less than 5 micron diameter) droplets. Droplet size and nebulisation time were inversely proportional to gas flow rate. Aerosol output and nebulisation time were increased by raising the volume fill from 2 to 4 ml, although nebulisation time could still be restricted to 12 minutes or less with DeVilbiss and Upmist at 12 1 . min-1. The output of drug in droplets of below 5 micron diameter ranged from 7.2 (SE 0.4) to 71.4 (4.3) mg, according to the type of nebuliser, flow rate, and volume fill. These studies suggest that for optimal drug delivery 4 ml gentamicin solution should be nebulised either at a fixed flow rate of 10-12 1 . min-1 or with a high flow compressor. Previous unsatisfactory clinical results with antibiotic aerosols may have been due in part to incorrect choice of nebuliser or inappropriate operating conditions, or both.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4060108      PMCID: PMC460168          DOI: 10.1136/thx.40.9.671

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  12 in total

1.  Pulmonary aerosol deposition in chronic bronchitis: intermittent positive pressure breathing versus quiet breathing.

Authors:  M B Dolovich; D Killian; R K Wolff; G Obminski; M T Newhouse
Journal:  Am Rev Respir Dis       Date:  1977-03

2.  Efficiency of nebulizers for depositing saline in human lung.

Authors:  T Asmundsson; R F Johnson; K H Kilburn; J K Goodrich
Journal:  Am Rev Respir Dis       Date:  1973-09

Review 3.  Conference on the scientific basis of respiratory therapy. Aerosol therapy. Steroid and antibiotic aerosols.

Authors:  M H Williams
Journal:  Am Rev Respir Dis       Date:  1974-12

4.  Effect of auxiliary air flow on the output characteristics of compressed-air nebulizers.

Authors:  T T Mercer; R F Goddard; R L Flores
Journal:  Ann Allergy       Date:  1969-05

5.  Inhaled antibiotics in cystic fibrosis.

Authors:  M A Wall; A B Terry; J Eisenberg; M McNamara; R Cohen
Journal:  Lancet       Date:  1983-06-11       Impact factor: 79.321

6.  Assessment of jet nebulisers for lung aerosol therapy.

Authors:  M M Clay; D Pavia; S P Newman; T Lennard-Jones; S W Clarke
Journal:  Lancet       Date:  1983-09-10       Impact factor: 79.321

7.  Physical properties of aerosols produced by several jet- and ultrasonic nebulizers.

Authors:  P J Sterk; A Plomp; J F van de Vate; P H Quanjer
Journal:  Bull Eur Physiopathol Respir       Date:  1984 Jan-Feb

8.  Factors influencing the size distribution of aerosols from jet nebulisers.

Authors:  M M Clay; D Pavia; S P Newman; S W Clarke
Journal:  Thorax       Date:  1983-10       Impact factor: 9.139

Review 9.  Therapeutic aerosols 1--physical and practical considerations.

Authors:  S P Newman; S W Clarke
Journal:  Thorax       Date:  1983-12       Impact factor: 9.139

10.  Production of therapeutic aerosols; principles and techniques.

Authors:  T T Mercer
Journal:  Chest       Date:  1981-12       Impact factor: 9.410

View more
  22 in total

Review 1.  Methods to identify drug deposition in the lungs following inhalation.

Authors:  H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

Review 2.  Management of acute pediatric asthma.

Authors:  John C Carl; Carolyn M Kercsmar
Journal:  Curr Allergy Asthma Rep       Date:  2002-11       Impact factor: 4.806

Review 3.  Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

4.  Nebulization of liposomes. II. The effects of size and modeling of solute release profiles.

Authors:  R W Niven; M Speer; H Schreier
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

5.  Inhaled micronised gentamicin powder: a new delivery system.

Authors:  J M Goldman; S M Bayston; S O'Connor; R E Meigh
Journal:  Thorax       Date:  1990-12       Impact factor: 9.139

6.  Selecting and using nebuliser equipment.

Authors:  A H Kendrick; E C Smith; R S Wilson
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

7.  Why nebulise for more than five minutes?

Authors:  C O'Callaghan; A R Clark; A D Milner
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

8.  Nebulisers: uses and abuses.

Authors:  S P Newman; S W Clarke
Journal:  Arch Dis Child       Date:  1986-05       Impact factor: 3.791

9.  Pulmonary deposition of nebulised pentamidine isethionate: effect of nebuliser type, dose, and volume of fill.

Authors:  M O'Doherty; S Thomas; C Page; C Bradbeer; T Nunan; N Bateman
Journal:  Thorax       Date:  1990-06       Impact factor: 9.139

10.  A radiometric study of factors affecting drug output of jet nebulizers.

Authors:  G Mittal; N Kumar; H Rawat; M K Chopra; A Bhatnagar
Journal:  Indian J Pharm Sci       Date:  2010-01       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.